PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease ReportsAlagille syndrome
MeSH D016738 - alagille syndrome
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D000015:Multiple abnormalities
0 Companies
0 Drugs
Success rate
D002780:Intrahepatic cholestasis
1 Company
1 Drug
$
Success rate
D030342:Inborn genetic diseases
4 Companies
3 Drugs
$
Success rate
D006330:Congenital heart defects
0 Companies
0 Drugs
Success rate
D016738: 
Alagille syndrome
1 Company
1 Drug
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Mirum PharmaceuticalsMaralixibat Livmarli  2022-12-09 $170.276 M Q3/23-Q2/24 
Clinical Trials
Historical Success Rate
Phase 1
50%
1/2
Phase 2
0%
0/1
Phase 3
0%
0/1
Approved: 0Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Mirum Pharmaceuticals
Maralixibat,
Maralixibat chloride,
Sodium chloride,
Aspartame
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use